Advertisement

Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study)

      Whether biomarkers associated with cardiovascular disease risk also predict incident diabetes mellitus (DM) is unknown. Our objective was to determine if a panel of 18 biomarkers previously associated with risk of cardiovascular disease also predicts incident DM in statin-treated patients with coronary artery disease (CAD). The Treating to New Targets (TNT) study is a randomized trial that compared the efficacy of high (80 mg) versus low (10 mg) dose atorvastatin for the secondary prevention of coronary heart disease events. Fasting plasma levels of standard lipids and of 18 emerging CAD risk biomarkers were obtained after an 8-week run-in period on atorvastatin 10 mg in a random sample of 1,424 TNT patients. After exclusion of patients with DM at baseline (n = 253), 101 patients developed DM during the median follow-up of 4.9 years. Patients with incident DM had lower levels of total and high-molecular weight adiponectin, lipoprotein-associated phospholipase A2 (Lp-PLA2), soluble receptor of advanced glycation end products, and vitamin D compared with patients without incident DM. In contrast, insulin, soluble CD40 ligand, and soluble intercellular adhesion molecule-1 levels were higher in patients with incident DM compared with those without. Plasma levels of C-reactive protein, cystatin C, lipoprotein(a), monocyte chemotactic protein-1, matrix metalloproteinase-9, myeloperoxidase, neopterin, N-terminal fragment of pro–B-type natriuretic peptide, osteopontin, and soluble vascular cell adhesion molecule-1 were comparable in patients with and without incident DM. After multivariate adjustment, total and high-molecular weight adiponectin as well as Lp-PLA2 were negatively associated with incident DM. Results of this study suggest that plasma lipids and some emerging CAD risk biomarkers, such as adiponectin and Lp-PLA2, may be useful for predicting incident DM in statin-treated patients with stable CAD.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Zimmet P.Z.
        • Magliano D.J.
        • Herman W.H.
        • Shaw J.E.
        Diabetes: a 21st century challenge.
        Lancet Diabetes Endocrinol. 2014; 2: 56-64
        • Wilson P.W.
        • Kannel W.B.
        • Silbershatz H.
        • D'Agostino R.B.
        Clustering of metabolic factors and coronary heart disease.
        Arch Intern Med. 1999; 159: 1104-1109
        • Waters D.D.
        • Ho J.E.
        • DeMicco D.A.
        • Breazna A.
        • Arsenault B.J.
        • Wun C.C.
        • Kastelein J.J.
        • Colhoun H.
        • Barter P.
        Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials.
        J Am Coll Cardiol. 2011; 57: 1535-1545
        • Arsenault B.J.
        • Barter P.
        • DeMicco D.A.
        • Bao W.
        • Preston G.M.
        • LaRosa J.C.
        • Grundy S.M.
        • Deedwania P.
        • Greten H.
        • Wenger N.K.
        • Shepherd J.
        • Waters D.D.
        • Kastelein J.J.
        • Treating to New Targets (TNT) Investigators
        Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers.
        PLoS One. 2014; 9: e114519
        • LaRosa J.C.
        • Grundy S.M.
        • Waters D.D.
        • Shear C.
        • Barter P.
        • Fruchart J.C.
        • Gotto A.M.
        • Greten H.
        • Kastelein J.J.
        • Shepherd J.
        • Wenger N.K.
        Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        N Engl J Med. 2005; 352: 1425-1435
        • Bluher M.
        • Mantzoros C.S.
        From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century.
        Metabolism. 2015; 64: 131-145
        • Li S.
        • Shin H.J.
        • Ding E.L.
        • van Dam R.M.
        Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis.
        JAMA. 2009; 302: 179-188
        • Yaghootkar H.
        • Lamina C.
        • Scott R.A.
        • Dastani Z.
        • Hivert M.F.
        • Warren L.L.
        • Stancakova A.
        • Buxbaum S.G.
        • Lyytikainen L.P.
        • Henneman P.
        • Wu Y.
        • Cheung C.Y.
        • Pankow J.S.
        • Jackson A.U.
        • Gustafsson S.
        • Zhao J.H.
        • Ballantyne C.M.
        • Xie W.
        • Bergman R.N.
        • Boehnke M.
        • el Bouazzaoui F.
        • Collins F.S.
        • Dunn S.H.
        • Dupuis J.
        • Forouhi N.G.
        • Gillson C.
        • Hattersley A.T.
        • Hong J.
        • Kahonen M.
        • Kuusisto J.
        • Kedenko L.
        • Kronenberg F.
        • Doria A.
        • Assimes T.L.
        • Ferrannini E.
        • Hansen T.
        • Hao K.
        • Haring H.
        • Knowles J.W.
        • Lindgren C.M.
        • Nolan J.J.
        • Paananen J.
        • Pedersen O.
        • Quertermous T.
        • Smith U.
        • Lehtimaki T.
        • Liu C.T.
        • Loos R.J.
        • McCarthy M.I.
        • Morris A.D.
        • Vasan R.S.
        • Spector T.D.
        • Teslovich T.M.
        • Tuomilehto J.
        • van Dijk K.W.
        • Viikari J.S.
        • Zhu N.
        • Langenberg C.
        • Ingelsson E.
        • Semple R.K.
        • Sinaiko A.R.
        • Palmer C.N.
        • Walker M.
        • Lam K.S.
        • Paulweber B.
        • Mohlke K.L.
        • van Duijn C.
        • Raitakari O.T.
        • Bidulescu A.
        • Wareham N.J.
        • Laakso M.
        • Waterworth D.M.
        • Lawlor D.A.
        • Meigs J.B.
        • Richards J.B.
        • Frayling T.M.
        • GENESIS Consortium; RISC Consortium
        Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes.
        Diabetes. 2013; 62: 3589-3598
        • Mayer Jr., O.
        • Seidlerova J.
        • Filipovsky J.
        • Timoracka K.
        • Bruthans J.
        • Vanek J.
        • Cerna L.
        • Wohlfahrt P.
        • Renata C.
        • Trefil L.
        Unexpected inverse relationship between impaired glucose metabolism and lipoprotein-associated phospholipase A2 activity in patients with stable vascular disease.
        Eur J Intern Med. 2014; 25: 556-560
        • Lee E.S.
        • Jiang J.
        • Sund G.C.
        • Simonson W.T.
        • Graham J.
        • Dietsch G.
        • Schimpf B.
        • Bieg S.
        • Peterman G.
        • Lernmark A.
        Recombinant human platelet-activating factor acetylhydrolase reduces the frequency of diabetes in the diabetes-prone BB rat.
        Diabetes. 1999; 48: 43-49
        • O'Donoghue M.L.
        • Braunwald E.
        • White H.D.
        • Lukas M.A.
        • Tarka E.
        • Steg P.G.
        • Hochman J.S.
        • Bode C.
        • Maggioni A.P.
        • Im K.
        • Shannon J.B.
        • Davies R.Y.
        • Murphy S.A.
        • Crugnale S.E.
        • Wiviott S.D.
        • Bonaca M.P.
        • Watson D.F.
        • Weaver W.D.
        • Serruys P.W.
        • Cannon C.P.
        • SOLID-TIMI 52 Investigators
        • Steen D.L.
        Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
        JAMA. 2014; 312: 1006-1015
        • White H.D.
        • Held C.
        • Stewart R.
        • Tarka E.
        • Brown R.
        • Davies R.Y.
        • Budaj A.
        • Harrington R.A.
        • Steg P.G.
        • Ardissino D.
        • Armstrong P.W.
        • Avezum A.
        • Aylward P.E.
        • Bryce A.
        • Chen H.
        • Chen M.F.
        • Corbalan R.
        • Dalby A.J.
        • Danchin N.
        • De Winter R.J.
        • Denchev S.
        • Diaz R.
        • Elisaf M.
        • Flather M.D.
        • Goudev A.R.
        • Granger C.B.
        • Grinfeld L.
        • Hochman J.S.
        • Husted S.
        • Kim H.S.
        • Koenig W.
        • Linhart A.
        • Lonn E.
        • Lopez-Sendon J.
        • Manolis A.J.
        • Mohler 3rd, E.R.
        • Nicolau J.C.
        • Pais P.
        • Parkhomenko A.
        • Pedersen T.R.
        • Pella D.
        • Ramos-Corrales M.A.
        • Ruda M.
        • Sereg M.
        • Siddique S.
        • Sinnaeve P.
        • Smith P.
        • Sritara P.
        • Swart H.P.
        • Sy R.G.
        • Teramoto T.
        • Tse H.F.
        • Watson D.
        • Weaver W.D.
        • Weiss R.
        • Viigimaa M.
        • Vinereanu D.
        • Zhu J.
        • Cannon C.P.
        • Wallentin L.
        Darapladib for preventing ischemic events in stable coronary heart disease.
        N Engl J Med. 2014; 370: 1702-1711
        • Laaksonen D.E.
        • Niskanen L.
        • Nyyssonen K.
        • Punnonen K.
        • Tuomainen T.P.
        • Valkonen V.P.
        • Salonen R.
        • Salonen J.T.
        C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men.
        Diabetologia. 2004; 47: 1403-1410
        • Pradhan A.D.
        • Manson J.E.
        • Rifai N.
        • Buring J.E.
        • Ridker P.M.
        C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.
        JAMA. 2001; 286: 327-334